APICHOPE PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.1 CNY | -5.55% |
|
-9.09% | -32.62% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,339 | 10,200 | 9,894 | 13,394 | 8,927 | - | - |
| Enterprise Value (EV) 1 | 6,339 | 10,200 | 9,894 | 13,394 | 8,927 | 8,927 | 8,927 |
| P/E ratio | 28.1 x | 33.6 x | 36.2 x | 71 x | 24.9 x | 19.6 x | 22.9 x |
| Yield | - | - | 0.58% | 0.7% | 0.5% | 0.65% | - |
| Capitalization / Revenue | 3.78 x | - | 4.34 x | 5.35 x | 3.21 x | 2.41 x | 2.43 x |
| EV / Revenue | 3.78 x | - | 4.34 x | 5.35 x | 3.21 x | 2.41 x | 2.43 x |
| EV / EBITDA | - | - | 26.7 x | 34.4 x | 14.6 x | 12.4 x | 11.9 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | 5.12 x | 5.37 x | 3.34 x | 2.85 x | 2.8 x |
| Nbr of stocks (in thousands) | 4,25,993 | 4,26,174 | 4,29,162 | 4,49,027 | 4,49,027 | - | - |
| Reference price 2 | 14.88 | 23.93 | 23.05 | 29.83 | 19.88 | 19.88 | 19.88 |
| Announcement Date | 29/03/21 | 20/04/22 | 19/04/23 | 26/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,675 | - | 2,280 | 2,503 | 2,777 | 3,705 | 3,674 |
| EBITDA 1 | - | - | 369.9 | 389.8 | 609.8 | 720.8 | 747.4 |
| EBIT 1 | - | - | 282 | 213.9 | 271.5 | 460.6 | 442.6 |
| Operating Margin | - | - | 12.37% | 8.55% | 9.78% | 12.43% | 12.05% |
| Earnings before Tax (EBT) 1 | - | - | 326.4 | 244.2 | 308.3 | 495 | 471.3 |
| Net income 1 | - | 306.9 | 290.7 | 184.6 | 333.4 | 462.3 | 394 |
| Net margin | - | - | 12.75% | 7.37% | 12.01% | 12.48% | 10.72% |
| EPS 2 | 0.5296 | 0.7133 | 0.6373 | 0.4200 | 0.8000 | 1.017 | 0.8667 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | 0.1333 | 0.2100 | 0.1000 | 0.1300 | - |
| Announcement Date | 29/03/21 | 20/04/22 | 19/04/23 | 26/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 14.6% | 8.14% | 8.77% | 12.5% | 11.6% |
| ROA (Net income/ Total Assets) | - | - | - | 8.07% | 6.2% | 8.67% | 8.1% |
| Assets 1 | - | - | - | 2,287 | 5,378 | 5,334 | 4,864 |
| Book Value Per Share 2 | - | - | 4.500 | 5.550 | 5.940 | 6.980 | 7.100 |
| Cash Flow per Share 2 | - | - | 1.100 | 1.010 | 1.350 | 1.410 | 1.570 |
| Capex 1 | - | - | 606 | 334 | 298 | 230 | 336 |
| Capex / Sales | - | - | 26.56% | 13.36% | 10.73% | 6.2% | 9.13% |
| Announcement Date | 29/03/21 | 20/04/22 | 19/04/23 | 26/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
19.88
CNY
Average target price
30.72
CNY
Spread / Average Target
+54.51%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.62% | 122.92Cr | |
| +20.37% | 4.33TCr | |
| +27.64% | 2.24TCr | |
| +19.88% | 1.55TCr | |
| +18.83% | 1.45TCr | |
| +54.69% | 1.29TCr | |
| -0.05% | 678.76Cr | |
| -11.39% | 655.78Cr | |
| +17.73% | 587.1Cr | |
| -8.87% | 572.55Cr |
- Stock Market
- Equities
- 300723 Stock
- Financials ApicHope Pharmaceutical Co., Ltd
